Title: RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant
phenotype of gastric cancer
Version: 2 Date: 07 Oct 2023
Reviewer:  Yuan-Feng Zeng
Reviewer's report:
Review comments
The manuscript is well, concisely and coherently presented. The title reflects the main subject
of the manuscript and the abstract summarizes the work described in the manuscript. Through
multidimensional bioinformatics analysis and functional validation experiments, the authors
proved that the key demethylase of m6A FTO promoted the malignant phenotype of GC cells
via regulating the oncogene related pathways. In addition, FTO improved the degradation of
MOXD1 mRNA via m6A modification. The elevated expression of MOXD1 was linked with
the promotion of malignant phenotype in GC cells, as well as unfavorable prognoses in GC.
The results are reliable and the conclusion is credible. So, my final review comment is to
recommend that the paper be accepted.
However, I  think there are two clerical errors in the manuscript in lines 173 and 234,
which explain the relationship between increased MOXD1 expression and prognosis in gastric
cancer patients. They contradict the relevant content explained in lines 253-254 and the results
presented in Figure 2. Please carefully check and verify by the authors.
Title: RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant
phenotype of gastric cancer
Version: 2 Date: 07 Oct 2023
Reviewer:  Yuan-Feng Zeng
Reviewer's report:
Review comments
The manuscript is well, concisely and coherently presented. The title reflects the main subject
of the manuscript and the abstract summarizes the work described in the manuscript. Through
multidimensional bioinformatics analysis and functional validation experiments, the authors
proved that the key demethylase of m6A FTO promoted the malignant phenotype of GC cells
via regulating the oncogene related pathways. In addition, FTO improved the degradation of
MOXD1 mRNA via m6A modification. The elevated expression of MOXD1 was linked with
the promotion of malignant phenotype in GC cells, as well as unfavorable prognoses in GC.
The results are reliable and the conclusion is credible. So, my final review comment is to
recommend that the paper be accepted.
However, I  think there are two clerical errors in the manuscript in lines 173 and 234,
which explain the relationship between increased MOXD1 expression and prognosis in gastric
cancer patients. They contradict the relevant content explained in lines 253-254 and the results
presented in Figure 2. Please carefully check and verify by the authors.
Please review this paper.
user
Title: RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant
phenotype of gastric cancer
Version: 2 Date: 07 Oct 2023
Reviewer:  Yuan-Feng Zeng
Reviewer's report:
Review comments
The manuscript is well, concisely and coherently presented. The title reflects the main subject
of the manuscript and the abstract summarizes the work described in the manuscript. Through
multidimensional bioinformatics analysis and functional validation experiments, the authors
proved that the key demethylase of m6A FTO promoted the malignant phenotype of GC cells
via regulating the oncogene related pathways. In addition, FTO improved the degradation of
MOXD1 mRNA via m6A modification. The elevated expression of MOXD1 was linked with
the promotion of malignant phenotype in GC cells, as well as unfavorable prognoses in GC.
The results are reliable and the conclusion is credible. So, my final review comment is to
recommend that the paper be accepted.
However, I  think there are two clerical errors in the manuscript in lines 173 and 234,
which explain the relationship between increased MOXD1 expression and prognosis in gastric
cancer patients. They contradict the relevant content explained in lines 253-254 and the results
presented in Figure 2. Please carefully check and verify by the authors.
assistant